Simultaneous determination of gastric cancer biomarkers pepsinogen PGI/PGII using element tagged immunoassay coupled with inductively coupled plasma mass spectrometry detection.

Abstract

ObjectivesIn this study, a new immunoassay for the simultaneous determination of pepsinogen I (PGI) and pepsinogen II (PGII) in serum based on element labeling strategy coupled with inductively coupled plasma mass spectrometry (ICP‐MS) detection was proposed.MethodsThe sandwich‐type immunoassay was used to simultaneously detect PGI and PGII in serum. PGI and PGII were captured by anti‐PGI and anti‐PGII antibody immobilized on the magnetic beads and then banded with Eu3+ labeled anti‐PGI detection antibody and Sm3+ labeled anti‐PGII detection antibody, followed by ICP‐MS detection.ResultsThe linear correlation coefficient (R 2) of PGI and PGII standard curves was .9938 and .9911, with the dynamic range of 0‐200 ng/mL and 0‐60 ng/mL, respectively. The limit of detection for PGI and PGII was 1.8 ng/mL and 0.3 ng/mL, respectively. The average recovery was 101.41% ± 6.74% for PGI and 101.47% ± 4.20% for PGII. Good correlations were obtained between the proposed method and CLIA (r = .9588 for PGI, r = .9853 for PGII).ConclusionsWe established a mass spectrometry‐based immunoassay for the simultaneous detection of PGI and PGII in a single analysis. The element tagged immunoassay coupled with ICP‐MS detection has high sensitivity, accuracy, and specificity in clinical serum sample analysis.